Population pharmacokineticpharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antibodies

Clinical Pharmacokinetics

Volumn 50, Issue 12, 2011, Pages 823-824

  Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Denosumab; Dose prediction; Metabolic bone diseases; Monoclonal antibodies; Osteoporosis; Pharmacokinetic modelling; Pharmacokinetics; Population pharmacokinetics

Indexed keywords

DENOSUMAB; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

BODY SIZE; BODY WEIGHT; DRUG BINDING; DRUG DISPOSITION; DRUG PROGRAM; DRUG TARGETING; HUMAN; NOTE; PHARMACODYNAMICS; PRIORITY JOURNAL; BIOLOGICAL MODEL; BLOOD; DRUG ANTAGONISM; FEMALE; METABOLIC BONE DISEASE; OSTEOPOROSIS;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; FEMALE; HUMANS; MODELS, BIOLOGICAL; OSTEOPOROSIS; RANK LIGAND;

EID: 81255143152     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11597950-000000000-00000     Document Type: Note

References (5)

1. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J 2008; 10 (4): 552-9
2. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011; 50 (12): 793-807
3. Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the targetmediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008; 35 (5): 573-91
4. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49 (10): 633-59
5. Wang DD, Zhang S, Zhao H, et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49 (9): 1012-24